Latest Breaking News On - Iterum therapeutics - Page 14 : comparemela.com

Iterum Therapeutics Announces Date of 1-for-15 Reverse

DUBLIN, Ireland and CHICAGO, Aug. 16, 2022 (GLOBE NEWSWIRE) Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical.

United statesJudy matthewsExchange commissionCompany board of directorsBoard of directors the companyNasdaq capital marketAnnual general meetingNasdaq listing ruleBid priceExchangeable senior subordinated notesIterum therapeuticsQualified infectious disease productFast trackAnnual reportNasdaq itrmIterum therapeutics plc

Iterum Therapeutics plc: Iterum Therapeutics Announces Date of 1-for-15 Reverse Share Split

DUBLIN, Ireland and CHICAGO, Aug. 16, 2022 (GLOBE NEWSWIRE) Iterum Therapeutics plc (Nasdaq: ITRM) (the "Company"), a clinical-stage pharmaceutical company focused on developing next generation

United statesJudy matthewsExchange commissionCompany board of directorsBoard of directors the companyNasdaq capital marketAnnual general meetingNasdaq listing ruleBid priceExchangeable senior subordinated notesIterum therapeuticsQualified infectious disease productFast trackAnnual report

Iterum Therapeutics Announces Special Protocol Assessment (SPA) Agreement With the FDA

SPA supports protocol for Phase 3 Clinical Trial of Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections Clinical Trial Expected to Begin Enrollment in Q4 2022 DUBLIN,.

United statesJudy matthewsCorey fishmanExchange commissionDrug administrationOral sulopenemUncomplicated urinary tractClinical trial expectedBegin enrollmentChief executiveIterum therapeuticsQualified infectious disease productFast trackNasdaq capital marketAnnual report

Iterum Therapeutics Shares Higher After FDA Agreement

Iterum Therapeutics Shares Higher After FDA Agreement
morningstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from morningstar.com Daily Mail and Mail on Sunday newspapers.

Michael dabaieDow jones company incDrug administrationIterum therapeuticsDow jones

Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesJudy matthewsCompany compensation committeeIterum therapeuticCompensation committeeNasdaq listing ruleEquity incentiveIterum therapeuticsQualified infectious disease productFast trackChief financial officer